EMA Withdrawn: Revasc (desirudin) — Canyon Pharmaceuticals Ltd.

View source ↗

Summary

MAH Canyon Pharmaceuticals withdrew Revasc (desirudin) from the EMA; therapeutic area venous thrombosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thrombosis

Drugs mentioned

• Revasc (desirudin)

Snippet

Status: Withdrawn. Therapeutic area: Venous Thrombosis. MAH: Canyon Pharmaceuticals Ltd.. Decision date: 23/01/2012